- $11.87m
- -$11.39m
- $1.98m
Biopharma firm Lipocine's Q3 net loss widens
Brief: Lipocine Q3 EPS USD -0.59
Brief: Lipocine Provides Progress Update On LPCN 1154 Phase 3 Clinical
Lipocine Inc reports results for the quarter ended June 30 - Earnings Summary
Lipocine Inc expected to post a loss of 40 cents a share - Earnings Preview
Brief: Lipocine Doses First Patient in Phase 3 Trial for LPCN 1154 in Postpartum Depression
Brief: Lipocine Announces Filing Of New Drug Submission For TLANDO In Canada
Lipocine Inc reports results for the quarter ended March 31 - Earnings Summary
Lipocine Inc expected to post a loss of 35 cents a share - Earnings Preview
Brief: Lipocine Announces Initiation of Outpatient Phase 3 Postpartum Depression Trial of LPCN 1154
Lipocine Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Lipocine to change FDA labeling for testosterone products
Lipocine Inc expected to post a loss of 40 cents a share - Earnings Preview
Brief: Lipocine Receives Updated Regulatory Guidance on LPCN 1154
Brief: Lipocine Announces Publication And Discussion Of LPCN 1148 Manuscript At The Liver Meeting 2024 Editor's Cut Session
Lipocine Inc reports results for the quarter ended in September 30 - Earnings Summary
Lipocine Inc expected to post a loss of 48 cents a share - Earnings Preview
Brief: Lipocine Announces Distribution And License Agreement With SPC Korea To Commercialize TLANDO In South Korea
Lipocine up as post-partum depression drug shows promising results in early stage study